Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maridebart cafraglutide - Amgen

Next Previous
Drug Profile

Maridebart cafraglutide - Amgen

Alternative Names: AMG-133; MariTide

Latest Information Update: 20 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Class Antihyperglycaemics; Bispecific antibodies; Drug conjugates; Heart failure therapies; Immunoconjugates; Obesity therapies; Peptides; Sleep disorder therapies; Vascular disorder therapies
  • Mechanism of Action Gastric inhibitory polypeptide receptor antagonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atherosclerosis; Heart failure; Obesity; Sleep apnoea syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 18 Nov 2025 Amgen plans a phase I trial for Obesity (SC), in November 2025 (NCT07229157)
  • 10 Nov 2025 Amgen plans a phase III (MARITIME-OSA-2) trial for Sleep apnoea syndrome in December 2025 (SC) (NCT07226765)
  • 07 Nov 2025 Amgen plans the phase III MARITIME-OSA-1 trial for Sleep apnoea syndrome (Adjunctive treatment) (SC, Injection), in December 2025 , (NCT07225686)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top